Blood Pressure Drug for COVID-Induced Lung Injury?

Despite promising results in preclinical models, angiotensin-receptor blockade with losartan did not reduce lung injury in hospitalized COVID-19 patients in this randomized clinical trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/972136?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?